scholarly journals A Pilot Study of Hepatic Irradiation with Yttrium90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma

2022 ◽  
Author(s):  
David R. Minor ◽  
Kevin B. Kim ◽  
Ricky T. Tong ◽  
Max C. Wu ◽  
Mohammed Kashani-Sabet ◽  
...  
Keyword(s):  
Pilot Study ◽  
Uveal Melanoma

scholarly journals Pilot study of anxiety, depression, and quality of life in patients with the diagnosis of metastatic uveal melanoma

2018 ◽  
Vol 29 ◽  
pp. viii560
Author(s):  
R. Nshimiyimana ◽  
C.E. Guzzetta ◽  
M.-M. Brown ◽  
Q. Zhou ◽  
J.M. Johnson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
Uveal Melanoma ◽  
Anxiety Depression

Adipophilin expression in primary and metastatic uveal melanoma: a pilot study

2017 ◽  
Vol 255 (5) ◽  
pp. 1049-1051 ◽  
Author(s):  
Miltiadis Fiorentzis ◽  
Helen Kalirai ◽  
Periklis Katopodis ◽  
Sarah E. Coupland
Keyword(s):  
Pilot Study ◽  
Uveal Melanoma

scholarly journals A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases

2019 ◽  
Vol 2 (4) ◽  
pp. e1183 ◽  
Author(s):  
Surein Arulananda ◽  
Sagun Parakh ◽  
Jodie Palmer ◽  
Mark Goodwin ◽  
Miles C. Andrews ◽  
...  
Keyword(s):  
Pilot Study ◽  
Uveal Melanoma ◽  
Yttrium 90

A pilot study of sunitinib malate in patients with metastatic uveal melanoma

2012 ◽  
Vol 22 (6) ◽  
pp. 440-446 ◽  
Author(s):  
Amit Mahipal ◽  
Lukman Tijani ◽  
Kathryn Chan ◽  
MaryAnn Laudadio ◽  
Michael J. Mastrangelo ◽  
...  
Keyword(s):  
Pilot Study ◽  
Uveal Melanoma ◽  
Sunitinib Malate

scholarly journals Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study

2017 ◽  
Vol 6 (6) ◽  
pp. e1321187 ◽  
Author(s):  
Yong Qin ◽  
Mariana Petaccia de Macedo ◽  
Alexandre Reuben ◽  
Marie-Andrée Forget ◽  
Cara Haymaker ◽  
...  
Keyword(s):  
Pilot Study ◽  
Uveal Melanoma ◽  
Cutaneous Melanoma ◽  
Immune Infiltrate ◽  
Similarities And Differences

scholarly journals Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases

2018 ◽  
Vol 4 (4) ◽  
pp. 227-240 ◽  
Author(s):  
Raymond Barnhill ◽  
Peter Vermeulen ◽  
Sofie Daelemans ◽  
Pieter-Jan van Dam ◽  
Sergio Roman-Roman ◽  
...  
Keyword(s):  
Pilot Study ◽  
Liver Metastases ◽  
Uveal Melanoma ◽  
Growth Patterns ◽  
Prediction Of Outcome ◽  
Histopathological Growth Patterns

Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8560-8560
Author(s):  
Matias Emanuel Valsecchi ◽  
Nancy Shockley ◽  
Deborah Summers ◽  
Carol L Shields ◽  
Jerry A Shields ◽  
...  
Keyword(s):  
Pilot Study ◽  
High Risk ◽  
Uveal Melanoma ◽  
Death Rate ◽  
Large Tumor ◽  
Primary Tumors ◽  
High Risk Patients ◽  
Monosomy 3 ◽  
Risk Patients ◽  
Melanoma Patients

8560 Background: Uveal melanoma is the most common primary intraocular cancer in adults. Despite the successful treatments for primary tumors, up to 50% of the patients later die of distant metastases. Currently no effective adjuvant treatment is available for these patients. Our group previously reported that sunitinib stabilized systemic metastases in 65% of uveal melanoma patients who failed prior treatments. In this pilot study, we tested sunitinib in an adjuvant setting in high-risk patients with primary uveal melanoma. Methods: Patients with estimated metastatic death rate ≥ 50% based on the following criteria were eligible: (1) monosomy 3 and 8q amplification; (2) large tumor (≥ 15 mm in diameter and ≥7 mm in thickness); (3) monosomy 3 and other risk factors (large tumor, epithelioid dominant cell type, local recurrence, or extra-scleral extension). Sunitinib was given at 25 mg PO daily for at least 6 months. Primary endpoint was disease-free survival (DFS) and overall survival (OS), estimated with Kaplan-Meier analysis (SPSS 17.0). Secondary endpoint was safety. Results: A total of 23 Caucasian patients (median, 54 years; range: 25 – 77) were enrolled. All patients received sunitinib for at least 6 months (range: 6 – 12). Eighteen patients had confirmed monosomy 3, from whom 13 (72%) also showed 8q amplification. The median follow-up was 24 months (range 12 – 54 months). Only one patient died of unknown cause (OS: 30.4 months). A total of seven patients (30%) developed systemic metastases, all of which were liver metastases. The DFS and OS rates at 2 years were 70% (95% CI: 47 – 86%) and 100%, respectively. The OS rate at 2 years was better than historical control with monosomy 3 patients (51%, 95% CI: 31 – 71%) (Invest Ophthalmol Vis Sci 2003; 44:1008). In those patients who relapsed, the median time to progression after finishing sunitinib was 2 months (range: 0 – 8). The most common adverse events were: diarrhea (47%), fatigue (39%), dermatitis (30%), stomatitis (13%), leucopenia (8%), and nausea (4%). Most were grade 1 or 2 (88%) and only one was considered grade 4 (diarrhea). Conclusions: In high-risk uveal melanoma patients with estimated metastatic death rate of ≥ 50%, adjuvant sunitinib showed promising results and deserves further investigation.

Sign in / Sign up

Export Citation Format

Share Document